Abiraterone for "STAMPEDE-Like" cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
170 patients were eligible, treated with hypofractionated RT with median prostate 2Gy-equivalent dose of 82 Gy.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
On multivariate analysis, Gleason score and nodal stage showed significant association with MFS. [CONCLUSION] For PSMA-PETCT staged high risk prostate cancer, appropriately intensified local treatment could be complementary or an alternative to systemic intensification in selected patients.
[PURPOSE] To assess long-term survival in a "STAMPEDE-like" cohort of high-risk locally advanced prostate cancer, staged with PSMA PET-CT, treated with hypofractionated radiotherapy (RT) and long-term
APA
Murthy V, Samanta A, et al. (2025). Abiraterone for "STAMPEDE-Like" cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?. Prostate cancer and prostatic diseases, 28(4), 985-988. https://doi.org/10.1038/s41391-025-00983-8
MLA
Murthy V, et al.. "Abiraterone for "STAMPEDE-Like" cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?." Prostate cancer and prostatic diseases, vol. 28, no. 4, 2025, pp. 985-988.
PMID
40404801 ↗
Abstract 한글 요약
[PURPOSE] To assess long-term survival in a "STAMPEDE-like" cohort of high-risk locally advanced prostate cancer, staged with PSMA PET-CT, treated with hypofractionated radiotherapy (RT) and long-term androgen deprivation therapy (LT-ADT) without abiraterone.
[MATERIALS & METHODS] Patients with non-metastatic prostate cancer fulfilling "STAMPEDE high-risk" criteria, staged with PSMA PET-CT, treated with external beam RT from 2016 to 2021 were included. RT dose was >74 Gy equivalent to prostate with LT-ADT ≥ 2 years. We analysed metastatic-free survival (MFS), prostate cancer specific survival (PCSS) and overall survival (OS) using Kaplan-Meier method.
[RESULTS] 170 patients were eligible, treated with hypofractionated RT with median prostate 2Gy-equivalent dose of 82 Gy. About one-third were node-positive and treated with whole pelvic RT. Over median follow up of 65 months, 6-years MFS, PCSS and OS were 80.7%, 95.8% and 94.4% respectively. On multivariate analysis, Gleason score and nodal stage showed significant association with MFS.
[CONCLUSION] For PSMA-PETCT staged high risk prostate cancer, appropriately intensified local treatment could be complementary or an alternative to systemic intensification in selected patients.
[MATERIALS & METHODS] Patients with non-metastatic prostate cancer fulfilling "STAMPEDE high-risk" criteria, staged with PSMA PET-CT, treated with external beam RT from 2016 to 2021 were included. RT dose was >74 Gy equivalent to prostate with LT-ADT ≥ 2 years. We analysed metastatic-free survival (MFS), prostate cancer specific survival (PCSS) and overall survival (OS) using Kaplan-Meier method.
[RESULTS] 170 patients were eligible, treated with hypofractionated RT with median prostate 2Gy-equivalent dose of 82 Gy. About one-third were node-positive and treated with whole pelvic RT. Over median follow up of 65 months, 6-years MFS, PCSS and OS were 80.7%, 95.8% and 94.4% respectively. On multivariate analysis, Gleason score and nodal stage showed significant association with MFS.
[CONCLUSION] For PSMA-PETCT staged high risk prostate cancer, appropriately intensified local treatment could be complementary or an alternative to systemic intensification in selected patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
- Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [Lu]Lu-PSMA-617: A Single-Center Retrospective Study.
- The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.
- Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with Lu-PSMA: A Retrospective, Single-Center Study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.